The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Authors
Keywords
-
Journal
BLOOD
Volume 135, Issue 8, Pages 523-533
Publisher
American Society of Hematology
Online
2019-12-03
DOI
10.1182/blood.2019000847
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
- (2019) Daisuke Ennishi et al. Cancer Discovery
- PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype
- (2019) James Godfrey et al. BLOOD
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
- (2019) Linda Hammerich et al. NATURE MEDICINE
- Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma
- (2019) Anja Mottok et al. BLOOD
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
- (2019) Marian L. Burr et al. CANCER CELL
- Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade
- (2019) Bjoern Chapuy et al. BLOOD
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
- (2019) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Mass cytometry of Hodgkin lymphoma reveals a CD4+exhausted T-effector and T-regulatory cell rich microenvironment
- (2018) Fathima Zumla Cader et al. BLOOD
- Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
- (2018) Valeria Spina et al. BLOOD
- How I treat primary mediastinal B-cell lymphoma
- (2018) Lisa Giulino-Roth BLOOD
- Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
- (2018) Max D. Wellenstein et al. IMMUNITY
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
- (2018) Marco Bezzi et al. NATURE MEDICINE
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
- (2018) Shixiang Wang et al. ONCOGENE
- Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
- (2018) Daisuke Ennishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumoral CD8 + T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
- (2017) Brendan L. Horton et al. Cancer Immunology Research
- Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas
- (2016) L. C. Chong et al. BLOOD
- Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
- (2016) K. Georgiou et al. BLOOD
- The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
- (2016) Colm Keane et al. CLINICAL CANCER RESEARCH
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Classical Hodgkin Lymphoma with Reduced 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
- (2016) M. G. M. Roemer et al. Cancer Immunology Research
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
- (2014) J. Reichel et al. BLOOD
- Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
- (2014) David D. W. Twa et al. BLOOD
- Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
- (2014) S. Riihijarvi et al. HAEMATOLOGICA
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
- (2014) Ronald Levy et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells
- (2013) P. Greaves et al. BLOOD
- Lung tumor NF-κB signaling promotes T cell–mediated immune surveillance
- (2013) Emily L. Hopewell et al. JOURNAL OF CLINICAL INVESTIGATION
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
- (2011) Madhavi Challa-Malladi et al. CANCER CELL
- Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
- (2011) Christian Steidl et al. JOURNAL OF CLINICAL ONCOLOGY
- High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma
- (2011) Qi-chun Cai et al. MEDICAL ONCOLOGY
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Inflammation meets cancer, with NF-κB as the matchmaker
- (2011) Yinon Ben-Neriah et al. NATURE IMMUNOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
- (2010) C. Steidl et al. BLOOD
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
- (2010) Christian Steidl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages as mediators of tumor immunosurveillance
- (2010) Siddhartha Jaiswal et al. TRENDS IN IMMUNOLOGY
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV
- (2008) V. Minard-Colin et al. BLOOD
- AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features
- (2008) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL)
- (2008) Kelly A. Cycon et al. EXPERIMENTAL HEMATOLOGY
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
- (2008) Richard K. Tsai et al. JOURNAL OF CELL BIOLOGY
- Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways
- (2008) M Booman et al. JOURNAL OF PATHOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started